Application
UBR1 Antibody (N-term) western blot analysis in mouse liver tissue lysates (35ug/lane).This demonstrates the UBR1 antibody detected the UBR1 protein (arrow).| Product Name | UBR1 Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | UBR1; E3 ubiquitin-protein ligase UBR1; N-recognin-1; Ubiquitin-protein ligase E3-alpha-1; Ubiquitin-protein ligase E3-alpha-I |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | UBR1 E3 ubiquitin-protein ligase UBR1 N-recognin-1 Ubiquitin-protein ligase E3-alpha-1 Ubiquitin-protein ligase E3-alpha-I |
|---|---|
| Molecular Weight(MW) | 200211 Da |
| Function | E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. May be involved in pancreatic homeostasis. Binds leucine and is a negative regulator of the leucine-mTOR signaling pathway, thereby controlling cell growth |
| Tissue Specificity | Broadly expressed, with highest levels in skeletal muscle, kidney and pancreas. Present in acinar cells of the pancreas (at protein level) |
| Cellular Localization | Cytoplasm, cytosol. |
| Entrez Gene | 197131 |
|---|---|
| Nucleotide Accession | NP_777576.1 |
Application
UBR1 Antibody (N-term) western blot analysis in mouse liver tissue lysates (35ug/lane).This demonstrates the UBR1 antibody detected the UBR1 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
